BERGISCH GLADBACH, – The new Viobility™ Fixable Dyes from Miltenyi Biotec allow the swift discrimination between live and apoptotic or dead cells by flow cytometry. The three dyes react with the primary amino groups of proteins. Optimized for various fluorescence channels, they are available from now on.

Miltenyi Biotec has developed the Viobility™ Dyes for the verification of and differentiation between living and dead cells. The dyes react with the primary amino groups of proteins and can permeate the weakened cell membranes of apoptotic and dead cells. The fluorescent staining of dead cells is therefore up to 50-fold brighter than on living cells. This makes it possible to measure the viability of a cell by using a flow cytometer, regardless of whether fixed or unfixed cells are analyzed.

The three new fluorophores, which are derived from the Vio® Dye Family, are optimized for various fluorescence channels:

Viobility™ 405/452 Fixable Dye (Ex.: 405 nm, Em.: 452 nm)

Viobility™ 405/520 Fixable Dye (Ex.: 405 nm, Em.: 520 nm)

Viobility™ 488/520 Fixable Dye (Ex.: 488 nm, Em.: 520 nm)

It is particularly in comparison with established dyes such as propidium iodide (PI) that the Viobility™ Dyes can display their advantages. Firstly, they don’t have any toxic effects on living cells. Secondly, they show less spillover into other fluorescence channels. In addition, Viobility™ Dyes facilitate higher flexibility in the design of antibody panels because they are available for various excitation and emission wavelengths.

All three dyes are available from Miltenyi Biotec in quantities sufficient for 100 or 500 tests.

For further information see the product page.

About Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Their more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific c